Navigation Links
BIND Biosciences To Install First Siemens Simatic(R) PCS 7 Lab Process Control System in the U.S.
Date:3/17/2009

ATLANTA, March 17 /PRNewswire/ -- Siemens Energy & Automation, Inc. announced today that BIND Biosciences, Inc., Cambridge, Mass., has selected Simatic(R) PCS 7 Lab hardware and software to help its scientists manage pre- and post-clinical experimental data.

(Logo: http://www.newscom.com/cgi-bin/prnh/20070904/SIEMENSLOGO )

BIND Biosciences develops targeted therapeutics based upon their novel polymeric nanoparticle drug delivery technology platform. It is the first company in the United States to install the PCS 7 Lab hardware and software.

With startup services provided by system integrator Optimation Technology, Inc., the phased automation implementation will help BIND Biosciences drive process development as well as monitor and control manufacturing operations.

"The flexibility and expandability of the PCS 7 Lab system will allow us to grow economically and efficiently through all three phases of the implementation," said Jeff Hrkach, BIND Biosciences Vice President of Pharmaceutical Sciences. "The system has all the tools we need to collect and manage our data as well as protect our intellectual property."

The PCS 7 Lab configuration, designed for laboratory and process development research and development applications, is based on Siemens Simatic PCS 7 Box. The UL certified system includes a preinstalled rack of I/O modules that can be easily reconfigured to fit any size or type of laboratory environment.

"This partnership with BIND gives Siemens the opportunity to help BIND bring drugs to market faster, " said Glenn Restivo, Siemens Life Sciences Industry Manager. "We adhere to the Design of Experiment and Quality by Design philosophies that build quality into every step of the process - from laboratory experimentation through every phase of manufacturing."

The implementation phase of the PCS 7 project is underway and focuses on basic experimentation and data collection. A second phase is under consideration for cataloging and organizing experimental data. Phase three, also under consideration, will include Siemens Sipat for Process Analytical Technology (PAT), Interspec for specification management and the R&D Suite for Electronic Lab Notebook (ELN).

About Siemens:

Siemens Energy & Automation, Inc. is one of Siemens' operating companies in the U.S. Headquartered in the Atlanta suburb of Alpharetta, Ga., Siemens Energy & Automation, Inc. manufactures and markets one of the world's broadest ranges of electrical and electronic products, systems and services to industrial and construction market customers. Its technologies range from circuit protection and energy management systems to process control, industrial software and totally integrated automation solutions. The company also has expertise in systems integration, technical services and turnkey industrial systems. For more information: www.sea.siemens.com.

Siemens AG (NYSE: SI) is a global powerhouse in electronics and electrical engineering, and operates in the industry, energy and healthcare sectors. For more than 160 years, Siemens has built a reputation for leading-edge innovation and the quality of its products, services and solutions. With 428,000 employees in 190 countries, Siemens reported worldwide sales of $116.6 billion in fiscal 2008. With its U.S. corporate headquarters in New York City, Siemens in the USA reported sales of $22.4 billion and employs approximately 69,000 people throughout all 50 states and Puerto Rico. For more information on Siemens in the United States, visit www.usa.siemens.com.


'/>"/>
SOURCE Siemens Energy & Automation, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Sangamo BioSciences to Present at the ThinkEquity Partners Growth Conference
2. Akers Biosciences, Inc. ABI or the Company Receipt of Further United States Military Contracts
3. Pressure BioSciences to Present at the Rodman & Renshaw BioFin 9th Annual Healthcare Conference in New York City on November 5th
4. Neurocrine Biosciences to Present at the CIBC World Markets 18th Annual Healthcare Conference
5. Pressure BioSciences, Inc. to Discuss Third Quarter Financial Results and Provide Business Update
6. Monogram Biosciences to Present at The Lazard Capital Markets Fourth Annual Healthcare Conference
7. Anaptys Biosciences Raises Over $33 Million in Series B Financing
8. YM BIOSCIENCES REPORTS FIRST QUARTER 2008 OPERATIONAL AND FINANCIAL RESULTS
9. Pressure BioSciences, Inc. Reports Third Quarter 2007 Financial Results and Provides Business Update
10. Schering-Plough Receives Clearance From U.S. Federal Trade Commission for Planned Acquisition of Organon Biosciences N.V.
11. Regado Biosciences to Present at 19th Annual Piper Jaffray Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2016)... ... May 27, 2016 , ... In response to meager public ... unaware of the plight of aphasia. In collaboration with the American Aphasia Association, ... , The link between stroke and aphasia is relatively unknown, but through collaboration ...
(Date:5/27/2016)... ... May 27, 2016 , ... Aimed at nurses and employees in the health ... of leaders in the nursing and health care industry. It also provides insight to ... Christian University. , As the nursing industry is coming out of one of ...
(Date:5/26/2016)... (PRWEB) , ... May 26, 2016 , ... Despite last ... meeting, expect Janet Yellen and company to wait until March 2017 for an interest ... University’s J. Mack Robinson College of Business. , “The Federal Open Market Committee (FOMC) ...
(Date:5/26/2016)... ... May 26, 2016 , ... Cabot Corporation, ... defective respirators, according to court documents and SEC filings. A jury has ... Tyler v. American Optical Corporation, Case No. BC588866, Los Angeles County, California. The ...
(Date:5/26/2016)... ... May 26, 2016 , ... Connor Sports, through its ... partner for the Tamika Catchings Legacy Tour that will commemorate the Indiana ... hardwood basketball surfaces in all forms and levels of the game, Connor Sports has ...
Breaking Medicine News(10 mins):
(Date:5/25/2016)... , May 25, 2016  According to Kalorama Information, ... billion in 2015.  Though these are challenging times ... opportunity for success for companies that remain optimistic ... of new growth prospects medical device companies spend ... and development (R&D) than do companies in other ...
(Date:5/25/2016)... MedDay, a biotechnology company focused on ... presentation entitled "High doses of biotin in progressive multiple sclerosis: ... by Professor Ayman Tourbah , Principal Investigator of the ... Academy of Neurology (EAN) in Copenhagen, Denmark ... take place on Sunday, 29 May 2016 from 14:45 to ...
(Date:5/24/2016)... May 24, 2016   ... beide primären Endpunkte und demonstriert Ebenbürtigkeit ... ‚ausgezeichneter plus guter , ... ,      (Logo: http://photos.prnewswire.com/prnh/20130829/633895-a ... neue positive Daten von der MORA-Studie der Phase ...
Breaking Medicine Technology: